Clinical and Experimental Allergy最新文献

{"title":"The Impact of Living With Inducible Laryngeal Obstruction.","authors":"Siobhan Ludlow, Lucie Byrne-Davis, Stephen J Fowler","doi":"10.1111/cea.70026","DOIUrl":"https://doi.org/10.1111/cea.70026","url":null,"abstract":"<p><p>Inducible Laryngeal Obstruction (ILO) is an inappropriate, transient, reversible narrowing of the larynx in response to external triggers. The aim of this qualitative study was to develop an in-depth understanding of the experiences of individuals living with ILO and the impact this has on their lives. We describe the impact the disease has on patients, and this should promote clinician awareness of the experience of ILO from the patient's perspective and support a personalised approach to care.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Immunotherapy Should Play a Key Role in Preschool Food Allergy Management.","authors":"Lianne Soller, Edmond S Chan, Scott B Cameron, Elissa M Abrams, Sandeep Kapur, Stuart N Carr, Timothy K Vander Leek","doi":"10.1111/cea.70013","DOIUrl":"https://doi.org/10.1111/cea.70013","url":null,"abstract":"<p><p>Food allergies pose significant challenges including the risk for severe allergic reactions. This review article highlights the advantages and disadvantages of the historic standard management approach-avoidance and carrying epinephrine in case of accidental ingestion-and argues, based on accumulating evidence, that oral immunotherapy (OIT) should play a key role in preschool food allergy management. Firstly, our review will highlight pitfalls with the 'wait-and-see' approach to natural resolution of food allergies, with recent data pointing to lower resolution than previously thought. For those who do not outgrow their allergies, waiting until school age to offer OIT means missing the window of opportunity where OIT is safest, and prolongs unnecessary dietary restrictions. For those who do outgrow their allergies, research indicates they may not reintroduce the food due to fear and aversion and can become re-sensitised, putting them at risk of severe reactions. Secondly, the risks associated with allergen avoidance are higher than previously believed. Allergen avoidance is imperfect and carries an increased risk of severe reactions when compared with the risk of severe reactions while on OIT, particularly in preschoolers. Although an allergic reaction can be stressful, it is preferable to have this occur during OIT where caregivers are vigilant following a scheduled dose, rather than having this occur at a potentially unexpected time following an accidental exposure. Lastly, there is a growing body of evidence supporting favourable safety and effectiveness of OIT in preschoolers, and preliminary data suggesting higher likelihood of remission in infants. OIT has the potential to significantly improve quality of life, and future research is needed to answer this important question in preschoolers. In summary, while ongoing research will further clarify cost-effectiveness, long-term adherence and psychosocial impacts of OIT, this review suggests that OIT should play a key role in preschool food allergy management.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hereditary Angioedema (HAE) in China: Advancing Awareness, Access, Advocacy and Alliances From the Greater Bay Area to the Global HAE Community.","authors":"Philip H Li, Jin-Xian Huang, Can-Tian Wang, Jane C Y Wong, Hao Chen, Bao Chai, Liang Chen, He Lai, Shuo Li, Yan-Hua Liang, Yun-Sheng Liang, Ning Liu, Bing Lu, Bao-Qing Sun, Qin-Tai Yang, Fei Ye, Jiang-Lin Zhang, Shu-Chen Zhang, Zuo-Tao Zhao, Min Zhou, Xian-Biao Zou, Guang-Hui Liu, Kai Guan","doi":"10.1111/cea.70014","DOIUrl":"https://doi.org/10.1111/cea.70014","url":null,"abstract":"<p><p>The article offers an overview of the progress in managing Hereditary Angioedema (HAE) in China, with a specific focus on the Greater Bay Area (GBA). Through the '4As' framework-Awareness, Access, Advocacy and Alliance-the article explores the challenges and advancements in HAE care. In terms of collaborative initiatives such as the HAE-ASIA (Angioedema Screening In Asia) collaboration and the GBA HAE Alliance \"Hub-and-Spoke model\" aim to bridge the gap between East and West, providing optimal patient care and advancing HAE management. By bridging the gap between East and West, the GBA aims to deliver optimal patient care and advance HAE management. Moving forward, it will be essential to persist in nurturing national and international collaborations, not only within China but also extending beyond its borders. These partnerships encourage the exchange of knowledge, research, and best practices, all of which are critical in propelling forward the care of HAE. By uniting as a worldwide community, we can significantly advance efforts to improve the quality of life for those affected by HAE across the globe.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Treatment Adherence in Allergic Rhinitis, Inflammasome Mechanisms in Asthma, and Chronic Cough: Insights From Recent Studies.","authors":"Mohamed H Shamji, Robert J Boyle","doi":"10.1111/cea.70023","DOIUrl":"https://doi.org/10.1111/cea.70023","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Dupilumab Treatment for Adult Allergic Bronchopulmonary Aspergillosis: A Real-World Analysis of 16 Cases in China.","authors":"Xu Li, Peng Jin, Na Liu, Tingting Gao, Yanfei Li, Lili Zhi","doi":"10.1111/cea.70020","DOIUrl":"https://doi.org/10.1111/cea.70020","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143522609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Conversation on Oral Immunotherapy for Preschool Children Must Continue.","authors":"Paxton Loke","doi":"10.1111/cea.70027","DOIUrl":"https://doi.org/10.1111/cea.70027","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143522723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Omalizumab Plus House Dust Mite Immunotherapy for Asthma: A Randomised, 5-Arm, Non-Blinded, Non-Placebo-Controlled, Multicentre, Interventional Trial.","authors":"Andrzej Bożek, Alicja Grzanka, Giorgio W Canonica","doi":"10.1111/cea.70021","DOIUrl":"https://doi.org/10.1111/cea.70021","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143481828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asthma With Fixed Obstruction Displays a Similar Small Airway Dysfunction to That Observed in Asthma-COPD Overlap.","authors":"Toshihiro Shirai, Keita Hirai, Yasuhiro Gon","doi":"10.1111/cea.70018","DOIUrl":"https://doi.org/10.1111/cea.70018","url":null,"abstract":"<p><p>The clinical characteristics of asthma patients with fixed airflow obstruction were compared with those with asthma-COPD overlap. Asthma patients with fixed airflow obstruction had comparable small airway dysfunction to asthma-COPD overlap patients.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143481745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab Efficacy and Safety in Patients With Persistent Asthma: Asia-Pacific Region.","authors":"Qingling Zhang, Nanshan Zhong, Sahajal Dhooria, Xiuhua Fu, Haohui Fang, Jie Lin, Shuyang Zhu, Elizabeth Laws, Yi Wang, Vivian Li, Chih-Chi Hu, Jennifer Maloney, Raolat M Abdulai, Lacey B Robinson","doi":"10.1111/cea.70005","DOIUrl":"https://doi.org/10.1111/cea.70005","url":null,"abstract":"<p><strong>Background: </strong>Asthma prevalence is increasing in the Asia-Pacific region. China and India account for > 35% of the world's population and are often underrepresented in clinical studies. This phase 3 study (NCT03782532) evaluated efficacy and safety of dupilumab, a monoclonal antibody blocking interleukin-4/13 signalling, in patients with persistent asthma from China and India.</p><p><strong>Methods: </strong>Patients (≥ 12 years) were randomised 1:1 to dupilumab 200 mg or matched placebo every 2 weeks for 24 weeks (primary analysis population: blood eosinophils ≥ 150 cells/μL or fractional exhaled nitric oxide ≥ 25 parts per billion without maintenance oral corticosteroid [OCS]; OCS maintenance population: 300 mg OCS).</p><p><strong>Primary endpoint: </strong>change from baseline to week 12 in forced expiratory volume in 1 s (FEV₁). Secondary endpoints: change from baseline to week 24 in 5-item Asthma Control Questionnaire (ACQ-5/7) scores, annualised severe exacerbation rate, and safety.</p><p><strong>Results: </strong>In the primary analysis population (n = 414), change in FEV₁ by week 12 was significantly greater for dupilumab versus placebo (least squares mean difference: 0.31 L [95% CI: 0.23-0.39]; p < 0.0001). At week 24, greater reductions in ACQ-5 score were seen for dupilumab versus placebo (least squares mean difference: -0.20 [95% CI: -0.35 to -0.05]; p = 0.0097). Dupilumab reduced severe exacerbation risk by 62% versus placebo during the treatment period (relative risk: 0.38 [95% CI: 0.21-0.70]; nominal p = 0.002). Safety was similar between treatment arms; injection-site reactions were more common with dupilumab treatment (5.0%) than with placebo (1.2%). The OCS maintenance population showed similar outcomes.</p><p><strong>Conclusion: </strong>Dupilumab significantly improved lung function and asthma control, numerically reduced asthma exacerbations, and was well tolerated in patients from China and India with persistent asthma and evidence of either type 2 inflammation or OCS maintenance.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier: NCT03782532.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143481827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Presentation and Nutrition Management of Non-IgE-Mediated Food Allergy in Children.","authors":"Marion Groetch, Carina Venter, Rosan Meyer","doi":"10.1111/cea.70012","DOIUrl":"https://doi.org/10.1111/cea.70012","url":null,"abstract":"<p><p>Non-IgE-mediated food allergy encompasses a wide spectrum of allergic disorders ranging from mild to severe presentations, including food protein-induced allergic proctocolitis, food protein-induced enterocolitis syndrome, and food protein-induced enteropathy. Other gastrointestinal symptoms such as constipation and gastroesophageal reflux disease have not previously been recognised as symptoms of non-IgE-mediated food allergy in food allergy guideline publications. Recently, two new consensus documents from the European Academy of Allergy, Asthma and Immunology address a potential role of food allergens in these disorders, where standard treatment has failed, and provide guidance for diagnosis and management of these conditions. Additional updates include the World Allergy Organisation guidance on the diagnosis and management of cow's milk allergy, the most commonly implicated food in non-IgE-mediated food allergy. These documents all help practitioners to distinguish between common manifestations in infancy that are not pathologic and non-IgE-mediated food allergy. Understanding diagnostic criteria is vital to prevent overdiagnosis, limit unnecessary elimination diets and preserve breastfeeding. Conversely, proper diagnosis may reduce symptoms in infants who are affected. Therefore, the first step in management of non-IgE-mediated food allergy is establishing a correct diagnosis, which requires understanding the clinical presentations and if needed, applying an appropriate short-term diagnostic elimination diet to observe for symptom resolution, followed by food reintroduction to assess for symptom recurrence. Once diagnosed, treatment requires removal of the trigger food, most commonly cow's milk, which is not without burden and nutrition risk. Non-IgE-mediated food allergies typically resolve early in childhood with some disorders resolving in infancy therefore early reassessment for tolerance is vital. Management of non-IgE-mediated food allergy entails following diagnostic algorithms, developing an individualised dietary plan, and timely assessment of tolerance development to reduce burden and nutrition risk.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}